Japanese generics firm Towa has made a small upward revision to its full-year forecast after its domestic business performed better than anticipated in H1. The firm is now expecting its domestic branch to net ¥129.5bn ($1.14bn) for the financial year ending March 2022, an increase of 1.3% on its originally-planned ¥127.8bn forecast for Japan announced in May.
The consolidated business – also including Towa’s overseas operations, largely gained through its buyout of the Pensa Investments generics division...








